Literature DB >> 1122669

Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.

E S Vesell, J R Shapiro, T Passananti, H Jorgensen, C A Shively.   

Abstract

In normal, nonmedicated volunteers and in patients with thyroid disorders the plasma half-lives of antipyrine, propylthiouracil, and methimazole were determined after single oral doses. The plasma half-liver plus or minus S.D. of antipyrine, propylthiouracil, and methimazole were 11.9 plus or minus 1.4 hr, 6.7 plus or minus 1.0 hr, and 9.3 plus or minus 1.4 hr, respectively, in normal volunteers, but were shortened to 7.7 plus or minus 1.2 hr, 4.3 plus or minus 0.7 hr, and 6.9 plus or minus 0.6 hr, respectively, in hyperthyroid patients. In hypothyroid patients the plasma half-lives of these drugs were prolonged to 26.4 plus or minus 4.0 hr, 24.7 plus or minus 34.5 hr, and 13.6 plus or minus 4.8 hr, respectively. Return to the euthyroid state restored plasma half-lives to or toward normal. Alterations in plasma drug half-lives during thyroid dysfunction appear to result mainly from accelerated hepatic microsomal drug metabolism in hyperthyroidism and retarded drug biotransformation during hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122669     DOI: 10.1002/cpt197517148

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Pharmacokinetics of propylthiouracil in man after intravenous infusion.

Authors:  J P Kampmann
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease.

Authors:  M Pokrajac; D Simić; V M Varagić
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

5.  Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog.

Authors:  T Ishizaki; K Tawara
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

6.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

7.  Single daily dose methimazole treatment of hyperthyroidism.

Authors:  D J Bouma; H Kammer
Journal:  West J Med       Date:  1980-01

Review 8.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Oxazepam pharmacokinetics in thyroid disease.

Authors:  A K Scott; A S Khir; P D Bewsher; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

10.  Pathophysiological changes that affect drug disposition in protein-energy malnourished children.

Authors:  Kazeem A Oshikoya; Idowu O Senbanjo
Journal:  Nutr Metab (Lond)       Date:  2009-12-01       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.